Article
5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity.
Mediators of inflammation - 1 Jan 2014
Stübig Thomas, Badbaran Anita, Luetkens Tim, Hildebrandt York, Atanackovic Djordje, Binder Thomas M C, Fehse Boris, Kröger Nicolaus
Abstract excerpt
Demethylating agent, 5-Azacytidine (5-Aza), has been shown to be active in treatment of myeloid malignancies. 5-Aza enhances anticancer immunity, by increasing expression of tumor-associated antigens. However, the impact of 5-Aza immune responses remains poorly understood. Here, T-cell mediated tumor immunity effects of 5-Aza, are investigated in vitro and in vivo. T-cells from healthy donors were treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.